RHYTHM PHARMACEUTICALS, INC. (RYTM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$87.6M
Cash & Equivalents
$44.2M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$6,265M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SETMELANOTIDE ACETATE
IMCIVREE |
APPROVED | Alström Syndrome (AS), Bardet Biedl Syndrome (BBS), Bardet-Biedl Syndrome, Child Obesity, Childhood-onset Combined Pituitary Hormone Deficiency, Cognitive Impairment, Gene Abnormality, Genetic Forms of Extreme Obesity, Genetic Obesity, Healthy, Hunger, Hyperphagia, Hypertriglyceridemia, Hypothalamic Obesity, LEPR Deficiency Obesity, Leptin Receptor Deficiency Obesity, Morbid Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Obese, Obesity, Obesity Associated With Defects in Leptin-melanocortin Pathway, Obesity Due to Melanocortin 4 Receptor Deficiency, Obesity, Childhood, Optic Nerve Hypoplasia, Overweight, Overweight and Obesity, PCSK1 Deficiency Obesity, Pituitary Stalk Interruption Syndrome, Polydactyly, POMC Deficiency, POMC Deficiency Obesity, Prader-Willi Syndrome, Pro-opiomelanocortin (POMC) Deficiency Obesity, Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations, PWS, Renal Insufficiency, Retinopathy, Septo-Optic Dyspl |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | PHASE3 | Active Not Recruiting | 296 |
| NCT06596135 | Open-Label Extension Study of Setmelanotide | PHASE3 | Enrolling By Invitation | 30 |
| NCT05774756 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | PHASE3 | Active Not Recruiting | 120 |
| NCT06772597 | A Study of Setmelanotide in Patients With Prader-Willi Syndrome | PHASE2 | Active Not Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.